Home - ExecEdge

Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s...

Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease

Aurora Cannabis Generates 55% Revenue Outside Canada as Medical Sales Surge – Quarterly Update Report

Enhanced Raises $50M to Fuel Next Phase, Backed by Major Investors

Fuel Up Your Portfolio with Suja Life’s Farm-to-Bottle Growth Strategy